Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)

U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).1 RINVOQ is expected to be available in the U.S. in late August … Continue reading Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)